EGM
BOLT icon

Engineers Gate Manager’s Bolt Biotherapeutics BOLT Stock Holding History

Engineers Gate Manager’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,620
Closed -$38.7K – 2174
2024
Q4 		$38.7K Buy
+3,620
New +$43.8K ﹤0.01% 2117

Other funds holding BOLT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Engineers Gate Manager's BOLT Position: Q1 2025 in Review

Engineers Gate Manager sold out of Bolt Biotherapeutics (BOLT) in Q1 2025, closing a stake of 3,620 shares — an estimated $38.7K sold.

Engineers Gate Manager first reported a position in BOLT in Q4 2024 and held it in 1 quarter. The position peaked at $38.7K in Q4 2024. 29 funds tracked by Wall St. Rank hold BOLT as of Q1 2025.

  • Engineers Gate Manager reported no remaining Bolt Biotherapeutics position as of Q1 2025 after selling out during the quarter.
  • Engineers Gate Manager sold 3,620 Bolt Biotherapeutics shares in Q1 2025, an estimated $38.7K.
  • Engineers Gate Manager first reported a position in Bolt Biotherapeutics in Q4 2024 and held it in 1 quarter.
  • Engineers Gate Manager's Bolt Biotherapeutics position peaked at $38.7K in Q4 2024.
  • 29 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q1 2025.

Based on Engineers Gate Manager's 13F filing for Q1 2025, filed 15 May 2025.